News & Updates

Azithromycin appears to only be as good as placebo in the treatment of preschool-age children presenting to the emergency department (ED) with moderate-to-severe acute wheezing, according to a study.

Dupilumab has been shown to reduce symptomatic, endoscopic, and histological eosinophilic esophagitis (EoE) markers for patients treated in routine practice, as shown in the retrospective DUPEOETALY study.

The novel antisense oligonucleotide bepirovirsen has induced functional cure in one-fifth of patients with chronic hepatitis B virus (HBV) infection in the phase 3 B-Well 1 and B-Well 2 trials.

Patients with radiographic axial spondyloarthritis (r-axSpA) who have been exposed to tumour necrosis factor inhibitor (TNFi) and interleukin (IL)-17 inhibitor (IL-17i) appear to have a lower risk of osteoporosis, but not hip fracture, than biologic disease-modifying antirheumatic drug (bDMARD)-naïve individuals, a recent study has shown.

Individuals with chronic hepatitis D (CHD) may benefit from lonafarnib boosted with ritonavir (LNF/RTV) alone or in combination with peg-interferon-alfa (PEG), findings from the phase III D-LIVR trial have shown.

Treatment with lutikizumab appears to improve outcomes in patients with moderate-to-severe hidradenitis suppurativa (HS) who have not responded to anti-TNF therapy, according to a phase II trial.

Tezepelumab demonstrates steroid-sparing potential in patients with severe asthma, reducing maintenance oral corticosteroid use while maintaining asthma control, as shown in the phase III SUNRISE study.